BMY vs. HALO: Bristol-Myers Squibb vs. Halozyme Therapeutics Stock Comparison

Company Profile

Bristol-Myers Squibb (BMY) and Halozyme Therapeutics (HALO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMY is classified in Pharmaceuticals while HALO is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; Bristol-Myers Squibb (BMY) at 44.01% also sits in the top quartile.

Both Bristol-Myers Squibb (BMY) at 18.47% and Halozyme Therapeutics (HALO) at 26.93% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Bristol-Myers Squibb (BMY) at 33.79% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Bristol-Myers Squibb (BMY) at -0.22% and Halozyme Therapeutics (HALO) at 37.55% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Bristol-Myers Squibb (BMY) at 1.59 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMY.

Only one side’s leverage can be read here: Bristol-Myers Squibb (BMY) carries debt-to-equity ratio of 1.91 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Bristol-Myers Squibb (BMY) at 13.78 and Halozyme Therapeutics (HALO) at 25.91 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Bristol-Myers Squibb (BMY) reports 5.43, ranking against industry peers normally.

Valuation Metrics